CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 0.98×, lower than 95% of its Biotechnology peers (median 2.86×)
- FinancialsAltman Z-Score 1.93: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.87BCNY279.02M · vs all stocks (USD)
Revenue (TTM)
514.89MCNY76.83M · vs all stocks (USD)
Profit Margin
-8.33%vs Biotechnology peers
Beta
0.3490xvs all stocks
52-Week Change
16.44%vs all stocks
Market Capitalization
1.87BCNY279.02M · vs all stocks (USD)
Enterprise Value
1.94BCNY289.26M · vs all stocks (USD)
Price to Sales (TTM)
3.67xvs Biotechnology peers
Price to Book (MRQ)
0.9802xvs Biotechnology peers
Enterprise to Revenue
3.77xvs Biotechnology peers
Enterprise to EBITDA
26.17xvs Biotechnology peers
Gross Margin
50.07%vs Biotechnology peers
Profit Margin
-8.33%vs Biotechnology peers
Operating Margin
-20.19%vs Biotechnology peers
Return on Assets (TTM)
-1.09%vs Biotechnology peers
Return on Equity (TTM)
-2.24%vs Biotechnology peers
Revenue (TTM)
514.89MCNY76.83M · vs all stocks (USD)
Revenue per Share (TTM)
1.62CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-13.40%vs Biotechnology peers
Gross Profit (TTM)
237.76MCNY35.48M · vs all stocks (USD)
EBITDA (TTM)
98.40MCNY14.68M · vs all stocks (USD)
Net Income (TTM)
-42.88MCNY-6.40M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.55%vs Biotechnology peers
Operating Cash Flow (TTM)
61.97MCNY9.25M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
52.81MCNY7.88M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
7.62MCNYFY2025 · Dec 31, 2025Revenue
514.09MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
261.59MCNYFY2025 · Dec 31, 2025Gross Profit
252.50MCNYFY2025 · Dec 31, 2025Operating Income
-38.23MCNY-5.70M · vs all stocks (USD)
Pre-tax Income
-61.83MCNYFY2025 · Dec 31, 2025Income Tax Expense
-5.82MCNYFY2025 · Dec 31, 2025Net Income
-56.01MCNYFY2025 · Dec 31, 2025EBIT
-50.58MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
98.40MCNYFY2025 · Dec 31, 2025Research & Development
22.32MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
185.50MCNYFY2025 · Dec 31, 2025Other Operating Expenses
19.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
11.25MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1743CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1743CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
317.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
317.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-56.01MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
588.64KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-28.77MCNYFY2025 · Dec 31, 2025Free Cash Flow
-49.87MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
280.45MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-56.01MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.76MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
16.41MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.93MCNYFY2025 · Dec 31, 2025Capital Expenditures
-21.10MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-1.31MCNYFY2025 · Dec 31, 2025Sale of Investments
182.76KCNYFY2025 · Dec 31, 2025Other Investing Activity
5.81MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-16.41MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
159.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-155.78MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-14.97MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.33MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-12.79MCNYFY2025 · Dec 31, 2025Shares Outstanding
318.00MSharesUpdated Sep 19, 2026Float Shares
209.17MSharesUpdated Sep 19, 2026% Held by Insiders
49.18%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
270.73MCNY40.40M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8510CNYUpdated Sep 19, 2026Total Debt (MRQ)
344.92MCNY51.47M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1783xvs Biotechnology peers
Current Ratio (MRQ)
1.35xvs Biotechnology peers
Book Value per Share (MRQ)
6.06CNYUpdated Sep 19, 2026Total Assets
2.64BCNY394.54M · vs all stocks (USD)
Total Current Assets
679.65MCNYFY2025 · Dec 31, 2025Total Liabilities
685.37MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.96BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
269.70MCNYFY2025 · Dec 31, 2025Total Current Liabilities
415.66MCNYFY2025 · Dec 31, 2025Cash
280.47MCNYFY2025 · Dec 31, 2025Cash Equivalents
252.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
280.47MCNYFY2025 · Dec 31, 2025Accounts Receivable
112.96MCNYFY2025 · Dec 31, 2025Inventory
101.31MCNYFY2025 · Dec 31, 2025Accounts Payable
48.07MCNYFY2025 · Dec 31, 2025Short-term Debt
220.84MCNYFY2025 · Dec 31, 2025Other Current Liabilities
8.41MCNYFY2025 · Dec 31, 2025Long-term Debt
138.37MCNYFY2025 · Dec 31, 2025Common Stock (Book)
318.00MCNYFY2025 · Dec 31, 2025Retained Earnings
83.58MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.96BCNY292.27M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
4.32CNYUpdated Sep 19, 202652-Week High
6.17CNYUpdated Sep 19, 202652-Week Change
16.44%vs all stocks
Beta
0.3490xvs all stocks
50-Day MA
5.30CNYUpdated Sep 19, 2026200-Day MA
5.15CNYUpdated Sep 19, 2026Avg 10-Day Volume
4.08MSharesUpdated Sep 19, 2026Avg 30-Day Volume
3.90MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.1300CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.98×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.98Industry median: 2.86Industry P5: 0.98Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.50Profit Margin: -0.08
Financial Health
Altman Z-Score 1.93: grey zoneSignificant
Altman Z-Score: 1.93
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule